Binding and agonist/antagonist actions of M35, galanin(1-13)-bradykinin(2-9) amide chimeric peptide, in Rin m 5F insulinoma cells

Kalev Kask, Malin Berthold, James Bourne, Siv Andell, Ülo Langel, Tamas Bartfai

Research output: Contribution to journalArticleResearchpeer-review

40 Citations (Scopus)


The chimeric peptide M35 [galanin(1-13)-bradykinin(2-9)amide] is a high-affinity galanin receptor ligand acting as a galanin receptor antagonist in the rat spinal cord, rat hippocampus and isolated mouse pancreatic islets. We have radiolabelled M35 and performed equilibrium binding studies with [125I]M35 on the rat pancreatic β-cell line Rin m 5F, whereby we show the existence of a high-affinity binding site (KD = 0.9 ± 0.1 nM) with a Bmax of 72 ± 3 fmol/mg protein. Galanin displaces [125I]M35 with the same affinity (KD = 1 nM) as it displaces [125I]galanin. Displacement of [125I]galanin by M35 from Rin m 5F cell membranes shows the presence of two binding sites for M35 with KD-values of 0.3 ± 0.1 nM and 0.52 ± 0.03 μM, respectively. The GTP- and pertussis toxin-sensitivity of M35 binding to Rin m 5F membranes shows that binding of [125I]M35 is almost completely abolished by the presence of GTP or after pertussis toxin treatment of the cells, indicating an agonist-like binding of M35 to the galanin receptors. M35 has a dual effect on the galanin mediated inhibition of forskolin stimulated cyclic AMP production in Rin m 5F cells: at low concentrations M35 antagonises the effect of galanin, whereas at concentrations above 10 nM M35 acts as a galanin receptor agonist. These agonist-like effects of galanin and M35 are not additive, thus the mixed agonist/antagonist properties arise from the chimeric nature of M35 [galanin(1-13)-bradykinin(2-9)amide] acting solely at galanin receptors.

Original languageEnglish
Pages (from-to)341-348
Number of pages8
JournalRegulatory Peptides
Issue number3
Publication statusPublished - 10 Nov 1995
Externally publishedYes


  • Chimeric peptide
  • Cyclic AMP production
  • Galanin receptor
  • Peptide antagonist
  • Rin m 5F insulinoma cell line

Cite this